Last reviewed · How we verify
NCT05834062
Phentermine/Topiramate as Preventive Pharmacotherapy for Obesity
Phase 2 trial testing Qsymia and lifestyle management therapy in Obesity, Adolescent. Withdrawn.
1 August 2026
Quick facts
| Lead sponsor | University of Minnesota |
|---|---|
| Phase | Phase 2 |
| Status | Withdrawn |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | quadruple |
| Primary purpose | treatment |
| Start date | 17 October 2023 |
| Primary completion | 1 August 2026 |
| Estimated completion | 1 August 2027 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Qsymia and lifestyle management therapy — full drug profile →
- Placebo and lifestyle management therapy
Conditions studied
- Obesity, Adolescent — all drugs for Obesity, Adolescent →
Sponsor
University of Minnesota
Who can join
Adults 16 to 22, any sex, with Obesity, Adolescent. Healthy volunteers can join.
What's being measured
Primary outcomes are the specific endpoints the trial is designed to prove or disprove.
-
Evaluate effects of preventive pharmacotherapy and lifestyle-based weight gain prevention on body mass index between the medication arm and the placebo arm
Time frame: 24 months
Change in BMI
Sponsor's own description
This study will test the use of phentermine and topiramate compared with placebo in helping adolescents who are at high risk for developing obesity to lose weight
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05834062
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Obesity, Adolescent
Currently open trials in the same condition.
- NCT06920862 — Multi-Modal Digital Interventions for Adolescent Weight Management · NA · recruiting
- NCT06822387 — Health Without Barriers/Salud Sin Barreras- Northern Colorado · NA · recruiting
- NCT06309121 — Effects of the Postbiotic Blend ABB C3 on Adiposity and Glucose Metabolism in Children and Adolescents · NA · active not recruiting
- NCT05982847 — National Blood Pressure Screening in Children to Improve Paediatric Healthcare in South Africa · recruiting
- NCT06515288 — Nutrition Goes to School: a School-based Nutrition Intervention to Promote Healthy Eating Behaviour Among Adolescents · NA · recruiting
Other University of Minnesota trials
Trials by the same sponsor.
- NCT02421497 — MRI Technical Development and Applications in Kidney Disease · not yet recruiting
- NCT04100109 — Evaluating the Metabolic Effects of Polylactose: A Novel Prebiotic · NA · withdrawn
- NCT05454306 — Anser Clavicle Pin for Surgical Management of Midshaft Clavicle Fractures · NA · withdrawn
- NCT03192007 — Multi-Parametric MRI for Renal Transplantation · not yet recruiting
- NCT04940533 — Pharmacokinetics of CFTR Modulators in Pregnant Individuals and in Postpartum Breastfeeding Mothers · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05834062 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of Minnesota
- Last refreshed: 23 October 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05834062.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing